Please find attached the Business report FY 2025. Attachment13-03-26 # Business Report – JCDecaux – FY2025

AVAILABILITY OF THE 2026 UNIVERSAL REGISTRATION DOCUMENT WITH THE ANNUAL FINANCIAL REPORT Regulated Information Paris, 13 March 2026 Societe Generale hereby informs the public that the French version of the 2026 universal registration document was filed with the French financial markets authority (The Autorité des Marchés Financiers – AMF) on 13 March 2026. The 2026 universal registration document includes the 2025 annual financial report which is made up of notably: •         the sustainability report, in accordance with the transposition into French law of Directive (EU) 2022/2464 of 14 December 2022, commonly known as the Corporate Sustainable Reporting Directive (CSRD) and with Commission Delegated Regulation (EU) 2023/2772 of 31 July 2023 setting out the sustainability reporting standards (European Sustainability Reporting Standards,...

SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2025 and provided corporate updates. FINANCIAL HIGHLIGHTSTotal revenue of Junshi Biosciences was approximately RMB2,498 million in 2025, representing an increase of approximately 28% compared to 2024, which was mainly due to the increase in revenue from sales of pharmaceutical products, in particular the domestic sales revenue of the company’s core product, toripalimab, was approximately RMB2,068 million, representing an increase of approximately 38% compared to 2024. Total research and development (“R&D”) expenses...

ATHENS, Greece, March 13, 2026 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: “DLNG”) (the “Partnership”), an owner of liquefied natural gas (“LNG”) carriers, today announced its results for the three and twelve months ended December 31, 2025. Twelve months Highlights:Net Income and Earnings per common unit (basic and diluted) of $61.6 million and $1.38, respectively; Adjusted Net Income(1) of $57.1 million and Adjusted Earnings per common unit(1) (basic and diluted) of $1.26; Adjusted EBITDA(1) of $109.2 million; and 99.3% fleet utilization(2).Quarter Highlights:Net Income and Earnings per common unit (basic and diluted) of $15.7 million and $0.38, respectively; Adjusted Net Income(1) of $14.1 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.34; Adjusted EBITDA(1) of $26.9 million; 98.8% fleet...

HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”) today reported financial and operating results for the fourth quarter and year ended December 31, 2025, while highlighting the advancement of the Company’s strategic transformation into a fully integrated industrial gas, energy, and carbon management platform.  MANAGEMENT COMMENTS “2025 was a transformational year for U.S. Energy, one defined by purposeful execution and a forward-looking vision,” said Ryan Smith, Chief Executive Officer of U.S. Energy Corp. “We deliberately optimized and monetized our conventional oil and gas portfolio to fund the development of something far more valuable: a fully integrated industrial gas, energy, and carbon management platform that we believe is fundamentally...

Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting TROP2  Achieved toxicology and manufacturing milestones for IM1240, demonstrating an expanded therapeutic window and commercially viable yield Positive preclinical data presented at ESMO Immuno-Oncology Congress 2025 demonstrates multi-arm anti-tumor activity for both IM1240 and IM1305 Total Cash Position of $9.5 million as of December 31, 2025, expected to provide runway into 2027 REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed...

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber institutional investors, expected to complete in the second quarter of 2026 Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune...

GRAND CAYMAN, Cayman Islands, March 13, 2026 (GLOBE NEWSWIRE) — Activate Energy Acquisition Corp. (NASDAQ: AEAQ) (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). Key Highlights from the Annual Report Include:Cash and Investments: Approximately $ 230,556,356 held in the trust account, invested in U.S. government securities or money market funds meeting certain conditions under Rule 2a-7 of the Investment Company Act.Operating Results: Net income of $ 300,371...

FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing of its credit facility. As a result, the Company enters 2026 with a strong foundation for successful growth LONDON, March 13, 2026 (GLOBE NEWSWIRE) —...

FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2025 on Friday, 27 March 2026 at 7am CET. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The conference call will be held on Friday, 27 March 2026 at 3pm CET / 2pm BST / 10am EDT / 7am PDT as a Teams webinar. To attend the webcast, register via this link. The presentation will be available on IBA’s investor relations website and on: https://www.iba-worldwide.com/iba-full-year-2025-results-press-release-conference-call...